Thursday, October 15, 2009

IGNT Cuts Manufacturing Costs and Increases Its Margins

YUCAIPA, Calif., Oct. 14, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News ), a leading Global Medical Device manufacturer focused in the $4 billion Respiratory Market for the growing ageing and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has received a proposal from a leading manufacturer to help reduce production costs and material costs by 50% for the manufacture of the Oxyview and the Oxyview Nasal Cannula.

As a part of improving product quality in large production, and reducing material and production costs to be more competitive in the respiratory marketplace, the company has received a proposal from a leading respiratory equipment manufacturer based in Pomona-California. The company CEO, and some of the management staff received a proposal on Wednesday last week to manufacture both the Oxyview and the Oxyview Nasal Cannula at 50% of the original costs from its current manufacturer and supplier. On Friday last week, they had a meeting in Pomona with the new manufacturer to discuss the new manufacturing and distribution of Oxyview and the new Oxyview Nasal Cannula.

"Now that we are selling our respiratory products, and sales have escalated, we must reduce our cost of goods sold in order to increase our profit margins and decrease the costs to our dealers and buyers. This change will give the company a stronger foot-hold in the market. We have a proprietary product and there is nothing in the marketplace that can compete with our device. We have gained support for all sectors of our industry, inclusive of leading respiratory equipment manufacturers, clinical foundations and more important, our shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.


INGEN TECHNOLOGIES, INC.
Stock Symbol :: IGNT
E-Mail this Article to a Friend
Print this Article
INGEN TECHNOLOGIES, INC. (IGNT) Ingen, Inc. manufactures medical devices and provides related services for medical and consumer markets primarily in the United States.
Recent Price $.0034
Market Capitalization $7.75M
Est Float 468M
Outstanding Shares 2.28B
Quotation OTC.PK

Ingen Technologies, Inc.

35193 Avenue "A"
Suite-C
Yucaipa, CA 92399


Phone: (800) 259-9622
Fax: 800-777-1186
http://www.ingen-tech.com
Similar Companies in Sector

Similar Companies in Sector

·
Lincare Holdings Inc. (Lincare) is a provider of oxygen and other respiratory therapy services to patients in the home. Lincare’s customers suffer from chronic obstructive pulmonary disease (COPD), such as emphysema, chronic bronchitis or asthma, and require supplemental oxygen or other respiratory therapy services in order to alleviate the symptoms and discomfort of respiratory dysfunction. Lincare primarily provides oxygen and other respiratory therapy services to patients in the home. NASDAQ:LNCR Recent Price: $.22.68

· American Homepatient, Inc. provides home healthcare services and products consisting primarily of respiratory therapy services, home infusion therapy services, and the rental and sale of home medical equipment and home health care supplies. The Company’s services and products are paid for primarily by Medicare, Medicaid, and other third-party payors. OTCBB:AHOM Recent Price: $.210



Current Projects

Oxyview Reaches Out to Entire COPD Community in the $4 Billion Respiratory Market

Ingen Technologies, Inc. recently announced that Oxyview was published in the March-2009 issue of HomeCare Magazine, and in the Spring-2009 issue of COPD Digest . COPD, chronic obstructive pulmonary disease, was the underlying cause of 718,077 U.S. deaths in 2000-2005, and it was the underlying cause of about 1 in 20 U.S. deaths for 2005 alone. With more than 20 million Americans diagnosed with COPD and another 12 million projected as being undiagnosed, Oxyview has an annual estimated projected revenue of $30M in the USA, and much greater in the global arena with an expected 600M COPD victims worldwide.

Ingen is Granted Patent Rights for China in Estimated $200M Market

Ingen Technologies, Inc. has announced that the Chinese State Intellectual Property for the People's Republic of China is prepared to grant patent rights for Oxyview. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought, according to researchers in Guangdong. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought. According to an estimation by the World Health Organization, COPD ranks first among the burdens of diseases in China and accounts for one million deaths and five million disabilities each year.



Company Overview

Ingen, Inc . (OTC.PK: IGNT)

Ingen Technologies brings over 20 years of experience and dedication to the design and support of medical devices, Ingen has helped many medical professionals meet clinical and economic objectives.

Ingen has developed medical products that provide a valuable benefit to the patient and cost savings to the insurance companies, Medicare and essentially the tax payer. The medical products provide a focus for the ever-increasing elderly population. These products are superior to any of our competition and they allow for effective medical product availability to seniors.

Ingen’s Mission: Our Commitment to Customers

Ingen is committed to meeting the needs of our customers through ongoing product innovation and support. Ingen distributes its products through a national distributor network domestically and in Canada, Asia and European Communities. Ingen’s commitment to customers continues beyond the sale of our product.

The Beginning

Ingen, originally a privately owned company founded for the purpose of providing medical solutions for our growing healthcare market, is now a publicly traded company and growing medical device manufacturer. In 1999, Ingen founders invested several millions of dollars in the research and development of state-of-the-art respiratory monitoring devices, with a focus on helping patients and preventing unnecessary costs to the healthcare system. With multiple patents, FDA classification and certifications, Ingen is the largest manufacturer of gravity-independent in-line oxygen flow meters, meeting the demand of the growing patient population and service providers. Our products are manufactured in the USA.

Our Capabilities

We are proud of our capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems.

Ingen Technologies, Inc. introduces Oxyview® , the World's First Patient In-Line Oxygen Flow-Meter. Another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients using oxygen. Oxyview® is reusable, requires no batteries, works all the time in any position with all liquid or gas O2 systems, and easily installs anywhere below the cannula nearest the patient where oxygen flow matters the most. Oxygen suppliers and patients will appreciate that Oxyview® prevents many unnecessary service calls.

Ingen Technologies is now offering a quality organic health supplement for patients using home oxygen therapy, and also to anyone else who is interested in healthy life styles. As a part of wellness, we are now offering the new Poga Moonga products. Poga Moonga includes a substance referred to as Moringa, and is extracted from the Moringa Tree. Ingen provides a drink or capsule that is efficiently absorbed by the bodies metabolism.

One bottle is 25.35 Ounces. The instructions say to take 1-3 oz daily, therefore one bottle should last between 8-25 days. A purchase includes 4 bottles or 1-3 months supply depending upon use.

Author Sanford Holst in “Moringa, Nature’s Medicine Cabinet,” writes,

"... it is said the Moringa tree prevent 300 diseases. Ancient Roman, Greek and Egyptian civilizations used...the (Moringa Tree)...It is best known as an excellent source of nutrition and a natural energy booster. Loaded with nutrients, vitamins and amino acids, it replenishes your body and provides what you need to through a hectic weekday or active weekend..." It produces long-lasting energy without hyperactivity...a nerve system at rest...a blood system not under pressure...a gland and hormone system in balance."

An L.A. Times article said,

Scientifically speaking, Moringa sounds like magic. It can rebuild weak bones, enrich anemic blood and enable a malnourished mother to nurse her staving baby. Doctors use it to treat diabetes in West Africa and high blood pressure in India...And, it’s not only good for you, it’s delicious." Mark Fritz, L.A. Times.

Perhaps the most remarkable thing about the Moringa is that it has such incredible health benefits over a wide-range of health issues. Here are but a few:

  • NUTRITION AND ENERGY BOOST
    While most people notice an energy boost right away, the nutritional results with undernourished people is staggering.
  • DETOXIFICATION
    In vitro studies show the Moringa’s ability to remove putrid waste from water. This is important for the planet. Over 6 million children are believed to die each year from infections caused by unclean water. It helps our bodies detoxify in much the same way.
  • ANTIBIOTIC
    Moringa works as a gentle, natural antibiotic,
    See Eilert, U.,B. Wolters and A. Nahrstedt. “The antibiotic principle of seeds of Moringa oleifera and Moringa stenopetala.” Journal of Medicinal Plant Research, 42, pp 55-61. 1981
  • SKIN TREATMENT
    And, like Aloe Vera, Moringa is believed to have great healing benefits for the skin. Most of the research is on topical applications, but the healing properties would extend to the body itself.
  • ANTI-INFLAMMATORY
    Indian traditional medicines have long used the Moringa in treating the body’s inflammation. See, Udupa, S.L., A.L. Udupa and D.R. Kulkarni, “Studies on the anti-inflammatory and wound healing properties of Moringa oleifera and Aegle marmelos. Fitoterapia 65(2) pp 119-123.
  • ULCERS
    The anti-ulcer effect of Moringa was reported in 1995 in Phytotherapy research. An extract was taken from dried leaves and showed an impressive ability to heal ulcers in lab animals. Holst, p17.
  • DIABETES
    An extract from the Moringa leaf has been shown to be effective in lowering blood sugar levels with a space of 3 hours. Holst, pp17-18.
  • SLEEP
    The leaf of the Moringa has been shown to aid in a calmer nervous system providing an improving in sleep. Holst, p18

In short some studies have proved Moringa leaves effective for treating,

  • Blood pressure
  • Diabetes
  • Colitis and Diarrhea
  • Used as a diuretic
  • Headache
  • Glandular swelling
  • Skin antiseptic
  • Fevers

Seeds are used for,

  • Fevers
  • Tumors
  • Rheumatism
  • Skin diseases
  • Prostate and bladder issues

Leadership

Scott R. Sand


Chief Executive Officer and Chairman of the Board

Thomas J. Neavitt


Chief Financial Officer

J.R. Marple


Senior Accountant

Ron Mitchell


Certified Public Accountant

William Denney


Auditor- Child, Van Wagoner and Bradshaw LLC

Christopher A. Wirth


Chief Operations Officer & Director

Bradley C. Klearman


Director and EVP of Sales & Distribution

David Wald


Office Manager

John Finazzo, MD


Director and Chairman of the Medical Advisory Board

Stephen O’Hara, MD


Director and Member of the Medical Advisory Board

Peter Wilke


Attorney

Donn Harms


Patent Attorney

Robert H. Sand


Chief Manufacturing Engineer

Richard Campbell


Product Design & Engineering




News

No comments: